Seeking Alpha

U.S. sales of Johnson & Johnson's (JNJ) drug-eluting stents plunged 63% to just $70M in Q4...

U.S. sales of Johnson & Johnson's (JNJ) drug-eluting stents plunged 63% to just $70M in Q4 as the pioneer takes back seat to Abbott (ABT). Worldwide, sales fell a milder 34.3% to $202M.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|